A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept
- 241 Downloads
We read the paper by Diaz et al.  which reported patients with rheumatoid arthritis (RA) who developed drug-induced lupus erythematosus (DILE) who were treated with rituximab. Although treatment recommendations for DILE are not currently available, patients with RA may have different drug options like rituximab which is also approved for the treatment of RA. However, in patients with ankylosing spondylitis (AS), options for the treatment of DILE are highly restricted since biologics other than anti-TNF agents (i.e., rituximab) have no proven efficacy [2, 3]. The challenge is the treatment of patients with AS who developed DILE while on the treatment of anti-TNF drugs; patients may inevitably exacerbate when TNF blockers stopped for the reversal of DILE symptoms and to continue non-steroid anti-inflammatory drugs (NSAIDs) alone may not be sufficient for the management.
Anti-TNF drugs are effective therapies for AS in terms of signs, symptoms, and functioning . Since the...
KeywordsRheumatoid Arthritis Inflammatory Bowel Disease Infliximab Ankylose Spondylitis Etanercept
- 1.Diaz JC, Vallejo S, Canas CA (2012) Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int 32(10):3315–3317Google Scholar
- 2.Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297PubMedCrossRefGoogle Scholar
- 12.van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA (2006) Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford) 45(10):1317–1319CrossRefGoogle Scholar